Introduction
============

Tuberculosis (TB) is the leading cause of death in human immunodeficiency virus (HIV)-infected individuals in countries with the highest TB burden [@B1]. Coinfection with HIV evidently affects the progression of *Mycobacterium tuberculosis* (*Mtb)*infection and induces *Mtb*-specific immune responses contributing to increased HIV replication through cellular activation [@B2], [@B3]. It is clear that the overall disruption of immune function in HIV infected patients is the sum of multiple factors including CD4^+^ T cell depletion by direct infection of HIV-1 and chronic immune activation leading to dysfunction of the immune system [@B4]. Pathologically HIV/TB coinfection caused functional disruption of local immune responses leading to weakened granulomatous host response to *Mtb* [@B5]. However, immune activation induced by rapid reactivation of *Mtb* in chronic HIV infection has not been fully investigated to our knowledge.

Granulysin is a member of the saposin-like protein family and co-localizes in the granular compartments of human natural killer (NK) cells, double negative invariant NKT (*i*NKT), Vgamma (γ) 9^+^Vdelta (d) 2^+^ T cells and CD8^+^ T cells along with granzymes and perforin [@B6]. It is a cationic small glycoprotein and synthesized as a secretary 15 kDa precursor which is then enzymatically processed into a granular 9 kDa protein. The 9 kDa isoform has characteristics of proinflammatory cytokine and cytolytic activity [@B7], which is able to induce cytolysis of various tumor cells, microbe-infected cells by release into the intercellular space between target and effector cells via granule exocytosis pathway upon stimulation [@B8] and mediates killing of extracellular and intracellular *Mtb* [@B9] via several effector molecules including perforin and granzymes. In contrast, the 15 kDa granulysin is constitutively secreted from NK and T cells via non-exocytotic pathway [@B10]. The CD8^+^ T, NK and even CD4^+^ T cells can express granulysin together with perforin and granzyme B co-localized in granules [@B11] and released into immunological synapse upon activation [@B12]. Granulysin-mediated lysis of *Mtb* infected cells has been performed mainly by CD8^+^ and NKT cells expressing perforin and granulysin [@B9], [@B13], [@B14]. High frequency of CD4^+^ T cells coexpressing granulysin was observed in children and adolescents [@B15]. Moreover, *i*NKT cells exhibiting antimycobacterial activity also expressed granulysin against *Mtb* inside monocytes/macrophages [@B14]. In addition, a reduced number of *i*NKT cells in peripheral blood were found in patients with pulmonary TB and HIV-1 infection [@B16]. In TB, granulysin and perforin could be detected in Vγ9^+^Vδ2^+^ T cells, indicating their direct contribution to a protective host response against *Mtb* infection [@B17].

Reduction of perforin and granulysin levels related to granzyme A has been reported in lung tissue biopsy from patients with chronic TB, while higher expression in CD8^+^ T cells was associated with bacteriological control, suggesting that perforin and granulysin could be used for evaluation of immune protection in human TB [@B18]. The primary effector function of CD4^+^ T cells is believed to be the production of interferon-gamma (IFN)-γ and other cytokines to activate macrophages, which can then control or eliminate intracellular organisms [@B19]. It has been shown that CD4^+^T cells were the main sources of IFN-γ and the relative responses to early secreted antigenic target (ESAT)-6 and culture filtrate protein (CFP)-10 significantly increased in even chronically HIV-infected patients with decreased CD4^+^T cells, whereas acute HIV infection induced a rapid depletion of *Mtb*-specific CD4^+^T cells in asymptomatic TB [@B20], [@B21]. In active pulmonary TB, high circulating IFN-γ level was detected which decreased significantly after two months of therapy [@B22], [@B23]. Similar results were found in child TB patients [@B24]. These indicate the involvement of IFN-γ in curative immune response against *Mtb*.

Significantly lower plasma granulysin levels than controls have been demonstrated in adults with active pulmonary TB in highly TB endemic area in Indonesia which increased after two months of anti-TB therapy, reaching the values similar to those of controls and even further increased after completion of anti-TB therapy. Such granulysin levels were predominantly in patients expressed by IFN-γ negative T cells suggesting that their cellular source of IFN-γ and granulysin in TB are partly non-overlapping [@B12]. Patients with active pulmonary TB had low circulating granulysin but high IFN-γ levels, indicating their possible role in host defense against *Mtb* [@B25]. Earlier study demonstrated that higher plasma IFN-γ was found in patients with HIV/TB coinfection than TB [@B26], suggesting a greater degree of immune activation in HIV/TB coinfection, particularly those with low CD4^+^ T cells counts.

There is limited information so far regarding the role of granulysin and other cytolytic effector molecules related to NK cells, *i*NKT cells, T cells and their subpopulations against *Mtb* infection in TB and HIV/TB coinfection. This study aims to investigate whether circulating granulysin and other effector molecules are associated with the number of corresponding functional cells, NK cells, *i*NKT cells, Vγ9^+^Vδ2^+^ T cells, CD4^+^ T cells and CD8^+^ T cells, and such association may influence the clinical outcome of the disease in patients with pulmonary TB and HIV/TB coinfection in northern Thailand where TB is endemic.

Materials and Methods
=====================

Study subjects
--------------

Six patients with HIV/TB coinfection and 21 TB patients were recruited from the outpatient and inpatient clinics of Chiang Rai Hospital and Mae Chan Hospital, north of Thailand. Pulmonary TB patients were categorized based on WHO criteria (WHO, 2009), defining whether or not the patients has previously received TB treatment. TB drug regimens were based on the recommendation of National Tuberculosis Program, Ministry of Public Health,Thailand. The patients with HIV/TB coinfection and TB were all newly diagnosed TB confirmed by microscopic examination of acid-fast bacilli (AFB) in sputum and positive cultures of *Mtb,*medical history and chest radiographic findings. All had never received any anti-TB therapy or taken anti-TB drugs for less than 7 days and never received any antiretroviral therapy, immune-suppressive drugs or other immunomodulators prior enrollment. None had diabetes mellitus or other acute infections. The patients with HIV/TB coinfection had not previously received highly active antiretroviral therapy (HAART), the standard drug treatment, and were positive for anti-HIV antibody by the particle agglutination assay (Serodia-HIV-1/2, Fujirebio Inc, Tokyo, Japan) and enzyme-linked immunosorbent assay (ELISA) (Enzygnost Anti-HIV 1/2 plus ELISA, or immunochromatographic rapid test (Determine HIV-1/2, Abbott Laboratories, Ill, USA) Dade Behring, Marburg, Germany). No patients were reported to be multidrug resistance (MDR) or extensively drug resistance (XDR) cases by drugs sensitivity tests at the time of enrollment. Eleven patients with HIV without receiving HAART (HIV+HAART-) and 17 with HIV receiving HAART (HIV+HAART+) were recruited from the HIV Care and Treatment Project (Daycare clinic). These patients had no previous TB episodes and had not received isoniazid preventive therapy (IPT) to sterilize latent TB infection (LTBI) and prevent progression to active TB at the time of enrollment. Their sputum smears were negative for AFB and *Mtb* cultures. They were negative (induration \< 5 mm) by Tuberculin Skin Test (TST) and had no concomitant active AIDS-related opportunistic infections within 30 days prior enrollment. The clinical characteristics of individual HIV/TB coinfection are summarized in Table [1](#T1){ref-type="table"}.

Twenty three healthy individuals recruited from Blood Bank of Mae Chan hospital was used as controls. They had no history of TB and no risk factors involving TB and their chest radiographs were normal. None of them had diabetes mellitus and all were negative for Hepatitis B surface antigen, Hepatitis C antigen and anti-HIV antibody.

This study was approved by the Ethical Review Committee for Research in Human Subjects, Ministry of Public Health, Thailand and the National Center for Global Health and Medicine, Japan, and the written informed consents were obtained from all patients and all healthy individuals.

Blood samples
-------------

Blood were collected in K~3~EDTA vacutainers upon enrollment (n = 6 for HIV/TB coinfection and 21 for TB) and after completion of anti-TB therapy for 6-9 months when they were considered as cured (n = 3 for HIV/TB coinfection and 13 for TB). Plasma were separated by centrifugation and stored at -80°C.

Determination of granulysin concentration
-----------------------------------------

The granulysin concentrations in plasma were determined by ELISA [@B25]. The test was done in duplicate. Briefly, a microtiter plate (Costar, USA) was coated with 100 µl/well containing 5 µg/ml mouse monoclonal anti-human granulysin (RB1) (MBL International Corporation, Nagoya, Japan) in 0.05 M carbonate-bicarbonate buffer (pH 9.5) and incubated overnight at 4^o^C. The plates were washed with phosphate buffered saline (PBS) containing 0.05% Tween 20 and blocked with buffered protein solution with ProClin-150 at room temperature (RT) for 1 h. After being washed, the undiluted plasma was added and incubated for 2 h at RT and followed by washing. The bound antigens were detected with 0.1 µg/ml of mouse monoclonal anti-human granulysin biotin (RC8) (MBL International Corporation) and avidin-horseradish peroxidase (Av-HRP) conjugate (BD Biosciences Phamingen, San Diego, CA) diluted to 1:1000. After incubation for 1 h, the reactions were developed by coloring with tetramethylbenzidine (TMB) substrate (BD Biosciences Phamingen) for 20 min in the dark. Optical densities were measured at 450/570 nm wave-length by a microplate reader (Sunrise; Tecan, Männedorf, Switzerland). The granulysin concentrations were calculated from the standard curve using granulysin in culture supernatant from Cos7 cell transfected with gene encoding 15 kDa granulysin. The lower detection limit for granulysin is 0.047 ng/ml.

Determination of perforin, granzyme B and IFN-γ
-----------------------------------------------

ELISA was used to determine the concentration of plasma perforin and granzyme B (MABTECH AB, Sweden), and IFN-γ (BD Biosciences Phamingen, San Diego, USA) according to the manufacture protocols. The test was done in duplicate. The detection limits of perforin, granzyme B and IFN-γ assays were 78, 8.78 and 4.7 pg/ml, respectively.

Western blot analysis
---------------------

The isoforms of granulysin with different molecular weight were analyzed by Western blot in 3 patients with HIV/TB coinfection and 3 with TB whose plasma were enough to be tested and one healthy controls (HC). The concentration of proteins with low molecular weight was performed by differential solublilization (DS)-method prior to SDS-PAGE and blotting [@B27]. Briefly, 36 µl of 7M urea/2M thiourea and 4 µl of 200 mM DTT were added to 20 µl of plasma and then mixed. The solution was dropped into 1.8 ml of purified acetone at 4°C with stirring and centrifuged at 19000 x g at 4°C for 15 min. Four hundred µl of 70% acetonitrile/12mM HCL were added to pellet and stirred at 4°C for 1 h. The solution was centrifuged at 19000 x g at 4°C for 15 min. The collected supernatant was subsequently dried by centrifugal concentrator (TAITEC, Koshigaya, Japan) and dissolved in 80 µl of 0.1% trifuluoroacetic acid. Equal volume of each sample was analyzed by SDS-PAGE, transferred onto 0.2 µm pore-size PVDF membrane (GE Healthcare, Buckinghamshire, UK) and then blotted with goat anti-granulysin polyclonal antibody (R&D, USA). Immunodetection was performed by incubation with HRP conjugated with rabbit anti-goat IgG (1:10000) (Cappel, MP Biomedicals, USA) and developed by ECL-prime detection reagents (GE Healthcare, USA).

Flow cytometric analysis
------------------------

Peripheral blood mononuclear cells (PBMCs) were isolated by a Ficoll-metrizonate density gradient centrifugation (Lymphoprep^TM^ tube, AXIS-SHIELD PoC AS, Oslo, Norway) and suspended in cold 10% FBS in RPMI 1640 medium (Gibco, Invitrogen, USA). In this study, the monocytes depleted PBMCs were used instead of PBMCs due to the need of monocytes in the separation study. To remove monocytes, PBMCs were re-suspended in cold separation buffer, incubated with microbeads conjugated to mouse anti-human CD14 monoclonal antibody (Miltenyi Biotec, Germany) and passed through a magnetic cell separation system (MACS, Miltenyi Biotech) on LS column. The viability of the cells determined by Trypan blue exclusion was ≥95%.

To determine the surface markers of NK cells (CD56^+^CD3^-^), *i*NKT cells (Vα24^+^CD3^+^), γδ T cells (Vγ9^+^Vδ2^+^CD3^+^), CD4^+^T cells (CD4^+^CD3^+^) and CD8^+^T cells (CD8^+^CD3^+^), the monocyte depleted PBMC were directly stained with a combination of fluorochrome-conjugated monoclonal antibodies (IMMUNOTECH, Beckman Coulter Company, France) for 30 min at 4°C in the dark and determined by flow cytometry using four-color immunofluorescent technique. Briefly, different cell populations were determined in 1x10^6^monocyte depleted PBMCs per tube using the specific antibodies conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), phycoerythrin-Texas Red-x (ECD) and phycoerythrin-cyanin5 (PC5) (IMMUNOTECH, Beckman Coulter Company, France) as follows: tube no. 1, FITC-labeled anti-Vγ9 (clone IMMU 360), PE-labeled anti-Vα24 (clone C15), ECD-labeled anti-CD3 (clone UCHT1) and PC5-labeled anti-CD8 (clone B9.11); tube no. 2, FITC-labeled anti-Vδ2 (clone IMMU389), PE-labeled anti-CD56 (clone N901), ECD-labeled anti-CD3 (clone UCHT1), and PC5-labeled anti-CD4 (clone 13B8.2). Mouse isotype IgG1-FITC (clone 679.1 Mc7), IgG1-PE (clone 679.1 Mc7), IgG1-ECD (clone 679.1 Mc7), and IgG1-PC5 (clone 679.1 Mc7) (IMMUNOTECH, Beckman Coulter Company, France) were used as isotype controls. After incubation, the erythrocytes were lysed with 500 µl of optilyse C lysis solution (Beckman Coulter, France) and incubated for 10 min at 4°C in the dark followed by adding 500 µl of PBS. The solutions were processed for flow cytometric analysis by four color detection EPICS^®^ XL™ Flow cytometer (Beckman Coulter, Japan) and the data were analyzed using the XL SYSTEM II™ software. Data were displayed as four-color dot plots.

Statistical analyses
--------------------

The data were analyzed using SPSS software version 18.0 (SPSS, Inc., Chicago, IL). The concentrations of granulysin, perforin, granzyme-B and IFN-γ in plasma and the surface markers expression on effector cells in each subject group were shown by median and interquartile range. Significant difference between two independent subject groups was compared by Mann-Whitney U test. Wilcoxon Signed Rank test was used to compare plasma granulysin and IFN-γ levels before and after completion of anti-TB therapy. The correlations among circulating granulysin, perforin, granzyme-B, IFN-γ and the number of NK cells, *i*NKT cells, Vγ9^+^Vδ2^+^ T cells, CD4^+^ T and CD8^+^ T cells were analyzed using a Spearman\'s rank correlation test. P value \< 0.05 was considered as statistical significance.

Results
=======

High granulysin and IFN-γ in HIV/TB, but low granulysin and perforin levels in TB
---------------------------------------------------------------------------------

The comparison of circulating granulysin, perforin and granzyme-B among patients with HIV/TB coinfection, TB, HIV+HAART- and HIV+HAART+ were shown in Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}. HIV/TB patients had significantly higher granulysin (median = 5.556 ng/ml, ranged 1.744-12.718) than TB patients (median = 0.905 ng/ml, ranged 0.735-1.272) (p = 0.001) and healthy controls (HC) (median=1.322 ng/ml, ranged 0.873-1.591) (p = 0.012) (Fig.[1](#F1){ref-type="fig"}A), while TB patients had significantly lower than those of HC (p = 0.003).

No significance difference in perforin levels was found in HIV/TB coinfection (median = 9418 pg/ml, ranged 4328-11386) and HC (median = 10363 pg/ml, ranged 7388-13430), while the levels in TB (median = 5538 pg/ml, ranged 4749-7519) were significantly lower than HC (p \<0.001) (Figure [1](#F1){ref-type="fig"}B). All study groups had granzyme-B levels as detection limit (Figure [1](#F1){ref-type="fig"}C). On average, IFN-γ levels were obviously higher in HIV/TB (median = 33.30 pg/ml, ranged 6.215-111.295) than TB patients (median = 11.08 pg/ml, ranged \<4.7-25.43) (p \< 0.001), and HC (median \<4.7 pg/ml, ranged \<4.7-15.09) (p \<0.001), respectively (Figure [1](#F1){ref-type="fig"}D).

Three different isoforms of circulating granulysin in patients with HIV/TB coinfection
--------------------------------------------------------------------------------------

When the granulysin were analyzed by DS-method and Western blot analysis***,***three bands were detected corresponding to isoforms with molecular weight of 17 kDa, 15 kDa and 9 kDa in plasma of patients with HIV/TB coinfection (Figure [2](#F2){ref-type="fig"}).

Small number of *i*NKT cells, Vγ9^+^Vδ2^+^ T cells and CD4^+^ T cells but high number of CD8^+^ T cells in HIV/TB coinfection
-----------------------------------------------------------------------------------------------------------------------------

Compared to TB, the number of *i*NKT cells, Vγ9^+^Vδ2^+^ T cells and CD4^+^ T cells was small but the number of CD8^+^ T cells was kept high in HIV/TB coinfection as shown in Figure [3](#F3){ref-type="fig"} and individual data of HIV/TB patients in Table [2](#T2){ref-type="table"}. Significantly higher number of NK cells in patients with TB (median = 1936 cells/µl, ranged 2016-2634) than HIV/TB patients (HIV/TB, median = 787 cells/µl, ranged 321-1303, p = 0.031) was observed.

Relatively smaller number of *i*NKT cells (median = 2 cells/µl, ranged 1-5) and CD4^+^ T cells (median = 146 cells/µl, ranged 39-327) were found in HIV/TB than TB patients (median of *i*NKT cells = 5 cells/µl, ranged 3-7, p = 0.029; median of CD4^+^ T cells = 589 cells/µl, ranged 375-732, p = 0.001). Vγ9^+^Vδ2^+^ T cells in HIV/TB coinfection (median = 7 cells/µl, ranged 6-46) also tended to be lower than those in TB (median = 52 cells/µl, ranged 16-94), although it was not significantly different. In addition, small number of CD8^+^ T cells was remarkable in TB (median = 339 cells/µl, ranged 249-485), whereas the CD8^+^ T cells in HIV/TB coinfection were kept high in circulation (median = 730 cells/µl, ranged 178-1499).

NK cells, CD8^+^ T cells, granulysin, perforin and IFN-γ in patients with HIV/TB coinfection and TB
---------------------------------------------------------------------------------------------------

The number of NK, *i*NKT, Vγ9^+^Vδ2^+^ T, CD4^+^T and CD8^+^ T cells were correlated with granulysin, perforin, granzyme-B and IFN-γ levels at the time of enrollment. In HIV/TB patients, NK cells and CD8+ T cells were not significantly correlated with granulysin, but both cell types positively correlated with perforin (p = 0.045, r = 0.714 and p = 0.036, r = 0.771, respectively). In TB patients, NK cells showed negative correlation, whereas CD8^+^ T cells was positively correlated with granulysin (p = 0.011, r = -0.499), p = 0.049, r = 0.398, respectively). For IFN-γ, a trend to increase in relation to the numbers of NK cells in patients with both HIV/TB coinfection and TB were seen. For the rest, no significant correlations were found among effector molecules and cell populations.

Increased circulating granulysin and decreased IFN-γ levels in HIV/TB coinfection and TB after completion of anti-TB therapy
----------------------------------------------------------------------------------------------------------------------------

After 6-9 months of anti-TB therapy, only 3 HIV/TB patients and 13 TB patients could be followed-up when they were considered as treatment success (Figure [4](#F4){ref-type="fig"}). In patients with HIV/TB coinfection, the granulysin levels after completion of anti-TB therapy (median = 8.535 ng/ml) showed a trend to increase compared to those before therapy (median = 7.365 ng/ml) (p = 0.208), although significant difference was not found (Figure [4](#F4){ref-type="fig"}A). Whereas in TB patients, the granulysin levels after completion of anti-TB therapy (median = 1.861 ng/ml) were significantly higher than those before therapy (median = 1.048 ng/ml) (p = 0.002) (Figure [4](#F4){ref-type="fig"}B).

In contrast, the IFN-γ levels after completion of anti-TB therapy were significantly lower in HIV/TB (median \<4.7 pg/ml) (Figure [4](#F4){ref-type="fig"}C) and TB patients (median \<4.7 pg/ml) (Figure [4](#F4){ref-type="fig"}D) than those before therapy (median = 53.04 pg/ml for HIV/TB, p = 0.037 and 10.04 pg/ml for TB, p = 0.012).

Clinical profiles in relation to effector molecules and cells in patients with HIV/TB coinfection
-------------------------------------------------------------------------------------------------

Among 6 HIV/TB patients, 4 were considered as cured, whereas 2 could not be followed-up (Table [1](#T1){ref-type="table"}). Among these, 3 patients with cured after 6-8 months of TB treatment had high granulysin and perforin levels and high number of NK cells (Table [2](#T2){ref-type="table"}). Obviously, they had very high CD8^+^ T cells. While one patient with cured after 18 months of TB treatment had quite low CD8^+^ T cells, but high NK cells and even very high IFN-γ levels, but the granulysin and perforin levels were lower than other 3 patients.

Discussion
==========

In this study, circulating granulysin and other immune molecules, perforin, granzyme-B and IFN-γ in relation to the numbers of NK cells, *i*NKT cells, Vγ9^+^Vδ2^+^ T cells, CD4^+^ T and CD8^+^ T cells in HIV/TB coinfection, TB and other control groups before and after completion of anti-TB therapy were investigated. Before anti-TB therapy, the extremely higher granulysin in HIV/TB coinfection and slightly lower granulysin in active pulmonary TB than HC were noted, and both increased after completion of anti-TB therapy, presumably indicating its protective role of host defense against *Mtb* infection. Low granulysin levels in active TB, may be explained by rapid consumption due to ongoing effector immune response, or reduced during active disease due to the reduction of T cell subsets dedicated to its production [@B12], [@B25]. Interestingly, the results of higher granulysin and perforin levels, higher number of NK cells and obviously higher number of CD8^+^ T cells in HIV/TB coinfection with cured after 6-8 months of TB treatment than the one with cured after 18 months upon therapy, indicated the effective role of NK cells in innate and CD8^+^ T cells in adaptive immunity. However, the patient with 18 months cured had high NK cells and obviously high IFN-γ levels suggesting the effective role in innate immunity. These results in Thai patients with HIV/TB coinfection were in accordance with the findings in Japanese patients with HIV/TB coinfection which also showed the higher plasma granulysin levels (median = 15.222 ng/ml, ranged 11.372-19.946, n = 19) than healthy individuals (median = 4.869 ng/ml, ranged 2.262-9.983, n = 19) (Figure [5](#F5){ref-type="fig"}) (Data provided by Dr. Shinichi Oka and his colleagues, AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan on November 1^st^, 2012). The explanation of the high granulysin in HIV/TB coinfection might be possibly due to (i) exposure to many antigens or with complication occurrences once those patients were concurrently infected with both pathogens as chronic infection which may influence quite high granulysin levels or (ii) the results of immune activation in HIV/TB coinfection or (iii) high number of CD8^+^ T cells may play a major cell for granulysin production.

In this study, three bands with ∼17 kDa, 15 kDa and 9 kDa were identified in plasma from HIV/TB coinfected patients. Though 9 kDa form of granulysin is cleaved from 15 kDa precursor by protease, it is known that 9 kDa form cannot be detected in normal plasma [@B10]. It is assumed that ∼17 kDa band may correspond to full length granulysin with signal sequence. Release of granulysin with signal peptide is questionable, except that from disrupted cells due to necrosis. So far, this is the first demonstration of granulysin in patients with HIV/TB coinfection using DS method to concentrate peptides and low molecular weight proteins in plasma.

High levels of granulysin coexisted with relatively large number of CD8^+^ T cells, but not proportional to *i*NKT, Vγ9^+^Vδ2^+^T, CD4^+^ T cells and NK cells in patients with HIV/TB coinfection in this study. In fact, the decreased CD4^+^ T cells in patients with HIV/TB coinfection were previously shown to be associated with failure of granuloma formation to contain *Mtb* infection, thereby causing mycobacterial dissemination [@B28]. Furthermore, activation of HIV-1 by *Mtb* components may be particularly important in viral expansion at the times when *Mtb* growth becomes exponential, and TB overwhelms host defenses [@B29]. Compared to HIV/TB coinfection, the significantly decreased *i*NKT, Vγ9^+^Vδ2^+^ T cells, CD4^+^ T cells, CD8^+^ T cells and increased NK cells in patients with TB before anti-TB therapy indicated the possibility that granulysin may be compromised by T cell subset with significantly correlated with CD8^+^ T cells. Obviously, increased NK cells were correlated with decreased granulysin, suggesting that it may not be released from NK cells, or granulysin inside the cells does not degranulated later upon activation. However, it could not be assured that (i) how much granulysin contained intracellularly and released to extracellular space since only free granulysin in circulation was measured in this study, (ii) how frequent expression of granulysin was induced in accumulated immune cells including CD8^+^ T cells at the TB-affected sites, particularly in patients with HIV/TB coinfection, (iii) the exact duration of being infected with *Mtb* until development to active disease with sputum AFB positive, (iv) how much granulysin was released in latent and early stage of active TB, and (v) varied granulysin levels may depend upon the nutrition and health status in individuals. Similarly, low perforin in TB were seen. The persistence of clinical disease was evidenced to be associated with deficient expression of perforin and granulysin at the local site of TB infection [@B18]. Although significant infiltration of CD4^+^ and CD8^+^ T cells was evidenced in TB lesions in patients with persistent inflammation [@B18], however, the levels of either perforin or granulysin remained low in TB lesions including severely impaired expression of these cytolytic effector molecules inside the distinct granules [@B18]. In the present study, either NK cells or CD8^+^ T cells were significantly correlated with the elevation of perforin in patients with HIV/TB coinfection but not in TB, indicating their potential functions in HIV/TB coinfection, as previously shown in individuals chronically infected with HIV-1 who have increased extracellular perforin levels compared with uninfected individuals, while the impaired functional activity of CTLs and NK cells during HIV-1 infection has been attributed to the decreased intracellular levels of perforin and granzyme B [@B30]. It is suggested that the induction of perforin has a distinct pathway from that of granulysin in HIV/TB coinfection in this study. However, in TB, no differences in granzyme B levels were found which is supported by similar results in slow or fast TB responders upon TB treatment at any time points and healthy individuals with PPD positive [@B31].

In contrast to granulysin, perforin and granzyme-B, the elevated circulating IFN-γ seen in patients with both HIV/TB coinfection and TB before anti-TB therapy which decreased after completion of therapy inferred a role of IFN-γ in effective immunity against *Mtb* infection. The results were similar to the previous report on significantly higher plasma IFN-γ levels in patients with active pulmonary TB than healthy individuals which decreased after treatment, suggesting that the levels may result from local production and spill-over of IFN-γ from activated lymphocytes sequestered at the site of *Mtb* infection [@B22], [@B24], [@B32]. In human and mouse models, IFN-γ is evidenced to be normally synthesized from CD4^+^ T cells activated upon recognition of *Mtb*antigen on antigen presenting cells [@B22] as well as by *Mtb* antigens specific CD8^+^ T cells [@B33]. Although IFN-γ producing CD4^+^ T cells of Th1 type is of major importance, however, other T cells notably CD8^+^ T cells and perhaps γδ T cells or CD1-restricted T cells participate in immune function as well [@B34]. However, increased CD4^+^ and decreased CD8^+^ T cells in TB in this study conversed to HIV/TB coinfection. Elevated IFN-γ levels in HIV/TB coinfection might be possibly due to the persistence of immune activation and chronically HIV associated TB. In addition, *Mtb*infection may support the HIV-1 replication and dissemination through dysregulation of host cytokines, chemokines and their receptors [@B29]. HIV/TB coinfection could inhibit cell mediated responses to *Mtb* through interruption of IL-2 signaling as well [@B35]. The deleterious effects of HIV infection in CD4^+^ T cells impair immune function as resulting in a failure to contain mycobacterial infection and restrict the replication of the microbe [@B36].

In this study, IFN-γ had a trend to increase along with NK cells in patients with both HIV/TB coinfection and TB, suggesting the possible production of IFN-γ from NK cells during initiation against *Mtb*infection which high NK cells were shown. It is also possible as recently shown that NK cells secrete IFN-γ which stimulates monocytes to produce IL-15 and IL-18, which in turn facilitates expansion of CD8^+^ T cells producing IFN-γ in response to *Mtb*-infected monocytes [@B37]. Since NK cells produce IFN-γ in early *Mtb* infection [@B38], therefore, this pathway is likely to be important in facilitating expansion of CD8^+^ T cells during immune response to *Mtb in vivo* [@B37].

In conclusion, the alteration of circulating granulysin, perforin and IFN-γ has potential function in host immune response in TB and HIV/TB coinfection. Circulating granulysin and perforin levels in TB were lower than healthy controls, whereas the granulysin levels in HIV/TB coinfection were much higher than in any other disease groups. Increased granulysin and decreased IFN-γ levels in HIV/TB coinfection and TB after completion of anti-TB therapy were noted. Slightly high perforin levels in HIV/TB coinfection indicated the immune activation in TB associated with HIV infection. Three distinct isoforms with ∼17kDa, 15kDa and 9kDa of granulysin were recognized in plasma of HIV/TB coinfection. The number of CD8^+^ T cells kept high but NK cells and other possible cellular sources of granulysin were decreased in HIV/TB coinfection, which in contrast to what seen in TB in which low CD8^+^ T cells but high NK cells were found, suggesting their different sources of granulysin, which in turn, play a crucial role in host defense against tuberculosis and in association with HIV infection. This is the first demonstration so far of granulysin in HIV/TB coinfection.
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![Isoforms of granulysin expression in plasma from Thai patients by Western blot analysis. Lane 1-3, HIV/TB coinfection plasma, 3 bands of ∼17kDa, 15kDa and 9kDa isoforms; Lanes: 4-6, TB plasma, I band of ∼17kDa isoform (Lane 4) and 2 bands of ∼15kDa and 9kDa isoforms (Lane 5-6); Lane 7, 2 bands of HC ∼15kDa and 9kDa isoforms.](ijmsv10p1003g02){#F2}

![The number of NK cells (A), *i*NKT cells (B), Vγ9^+^Vδ2^+^ T cells (C), CD4^+^ T cells (D) and CD8^+^ T cells (E) per microliter (µl) in Thai patients with HIV/TB coinfection and TB in comparison with healthy controls (HC), HIV+HAART- and HIV+HAART+ determined by flow cytometric analysis. Each dot represented one individual. A horizontal bar indicated the median of each group. \*, *p* \<0.05; \*\*, *p* \<0.01.](ijmsv10p1003g03){#F3}

![Circulating granulysin (ng/ml) and IFN-γ (pg/ml) in Thai patients with HIV/TB coinfection (A and C) and patients with TB (B and D) before and after completion of anti-TB therapy. Each dot represented one individual. \*, *p* \<0.05.](ijmsv10p1003g04){#F4}

![Circulating granulysin (ng/ml) in Japanese patients with HIV/TB coinfection before anti-TB therapy, HIV+HAART- and healthy controls (HC). Each dot represented one individual. A horizontal bar indicated the median of each group. \*, *p*\<0.05.](ijmsv10p1003g05){#F5}

###### 

Clinical characteristics of patients with HIV/TB coinfection.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                       Patient 1           Patient 2                                     Patient 3   Patient 4                               Patient 5                                 Patient 6
  ---------------------------------------------------- ------------------- --------------------------------------------- ----------- --------------------------------------- ----------------------------------------- --------------------------------
  Sex/Age                                              Male/42             Male/47                                       Male/44     Female/46                               Male/30                                   Male/37

  CXR findings at TB diagnosis                         Non-cavitary        Non-cavitary, infiltrates, pleural effusion   Cavitary    Non-cavitary                            Non-cavitary                              Non-cavitary, pleural effusion

  Presenting form of TB                                Pulmonary           Pulmonary + extra-pulmonary (meningeal)       Pulmonary   Pulmonary + extra-pulmonary (colitis)   Pulmonary + extra-pulmonary (lymp node)   Pulmonary

  Treatment regimen for TB                             2HRZE/4HR           2HRZE/4HR                                     2HRZE/4HR   2HRZE/4HR                               2HRZE/4HR                                 2HEOS/18HE

  HAART initiation during study period^\*^ (regimen)   Yes (d4T,3TC,NVP)   No                                            No          No                                      No                                        Yes\
                                                                                                                                                                                                                       (d4T,3TC,EFV)

  Outcomes after 6-9 mo of anti-TB therapy\            Cured\              Cured\                                        Cured\      N/A**^\*\*^**\                          N/A**^\*\*^**\                            Cured\
  Duration of TB treatment (month)                     7                   6                                             8           -                                       -                                         18
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

d4T = Stavudine; 3TC = Lamivudine; NVP = Nevirapine; EFV = Efavirenz; HAART = highly active antiretroviral therapy. **^\*^**HAART initiated 2 months after starting anti-TB treatment. **^\*\*^** Unable to follow-up.

###### 

Levels of circulating granulysin, perforin, granzyme-B and IFN-γ and number of effector cells in patients with HIV/TB coinfection before anti-TB therapy.

  Characteristic                   Patient 1   Patient 2   Patient 3   Patient 4   Patient 5   Patient 6
  -------------------------------- ----------- ----------- ----------- ----------- ----------- -----------
  Granulysin (ng/ml)               3.746       7.365       9.841       1.313       21.35       1.887
  Perforin (pg/ml)                 10763       10305       13255       8530        1722        5197
  Granzyme-B (pg/ml)               41.33       \<8.79      26          \<8.79      \<8.79      \<8.79
  IFN-γ (pg/ml)                    89.54       53.04       6.72        \<4.7       13.56       176.56
  NK cells (cells/µl)              646         991         2239        346         244         928
  *i*NKT cells (cells/µl)          8           2           4           2           1           1
  Vγ9^+^Vδ2^+^T cells (cells/µl)   44          7           6           53          4           3
  CD4^+^ T cells (cells/µl)        46          198         344         321         94          19
  CD8^+^ T cells (cells/µl)        854         2068        1309        606         181         168
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